167 related articles for article (PubMed ID: 24559448)
1. Tumor heterogeneity and personalized cancer medicine: are we being outnumbered?
Cirkel GA; Gadellaa-van Hooijdonk CG; Koudijs MJ; Willems SM; Voest EE
Future Oncol; 2014 Feb; 10(3):417-28. PubMed ID: 24559448
[TBL] [Abstract][Full Text] [Related]
2. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Arnedos M; Vielh P; Soria JC; Andre F
J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
[TBL] [Abstract][Full Text] [Related]
3. The search for optimal response prediction in cancer leads to a personalized approach.
Van Cutsem E; Ciardiello F
Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283
[No Abstract] [Full Text] [Related]
4. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic?
Roukos DH
Expert Rev Proteomics; 2012 Aug; 9(4):349-53. PubMed ID: 22967071
[No Abstract] [Full Text] [Related]
5. Recent advances and current issues in single-cell sequencing of tumors.
Sun HJ; Chen J; Ni B; Yang X; Wu YZ
Cancer Lett; 2015 Aug; 365(1):1-10. PubMed ID: 26003306
[TBL] [Abstract][Full Text] [Related]
6. Molecularly targeted cancer therapy: some lessons from the past decade.
Huang M; Shen A; Ding J; Geng M
Trends Pharmacol Sci; 2014 Jan; 35(1):41-50. PubMed ID: 24361003
[TBL] [Abstract][Full Text] [Related]
7. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
8. Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.
Picker A; Jackson DB
Expert Rev Mol Diagn; 2011 Jul; 11(6):567-77. PubMed ID: 21745011
[TBL] [Abstract][Full Text] [Related]
9. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.
Lee AJ; Swanton C
Biochem Pharmacol; 2012 Apr; 83(8):1013-20. PubMed ID: 22192819
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
11. [Discrepancies between primary tumor and metastasis: impact on personalized medicine].
Vignot S; Soria JC
Bull Cancer; 2013 Jun; 100(6):561-8. PubMed ID: 23728079
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
[TBL] [Abstract][Full Text] [Related]
13. The future of glioma treatment: stem cells, nanotechnology and personalized medicine.
Rahman M; Hoh B; Kohler N; Dunbar EM; Murad GJ
Future Oncol; 2012 Sep; 8(9):1149-56. PubMed ID: 23030489
[TBL] [Abstract][Full Text] [Related]
14. Cancer biomarkers, companion diagnostics and personalized oncology.
Ross JS
Biomark Med; 2011 Jun; 5(3):277-9. PubMed ID: 21657836
[No Abstract] [Full Text] [Related]
15. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-driven patient selection for early clinical trials.
Dienstmann R; Rodon J; Tabernero J
Curr Opin Oncol; 2013 May; 25(3):305-12. PubMed ID: 23493192
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers in the treatment of metastatic colorectal cancer.
Wilson PM; Labonte MJ; Lenz HJ
Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
[TBL] [Abstract][Full Text] [Related]
18. The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response.
Schwarzenbach H
Expert Rev Mol Diagn; 2015 Feb; 15(2):267-75. PubMed ID: 25382372
[TBL] [Abstract][Full Text] [Related]
19. The paradigm of personalized therapy in oncology.
Gasparini G; Longo R
Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S7-16. PubMed ID: 22073968
[TBL] [Abstract][Full Text] [Related]
20. Personalized medicine in oncology: tailoring the right drug to the right patient.
Jiang Y; Wang M
Biomark Med; 2010 Aug; 4(4):523-33. PubMed ID: 20701441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
